Xu et al. reported an ultrasound-activated therapy using piezoelectric nanocatalysts that triggers PANoptosis—a combined inflammatory cell-death program—in tumor models. The approach uses focused ultrasound to activate nanocatalysts in situ, producing reactive species that engage multiple death pathways and induce tumor regression. The team demonstrated efficacy in preclinical cancer models and characterized immune activation that may synergize with immunotherapies. Authors emphasize the noninvasive activation and multimodal cell-death induction as potential advantages for treating solid tumors refractory to single‑mode therapies.